MetabolicStrong Evidence

Tirzepatide

Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist

Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.

Benefits

6

Conditions

5

Evidence

SURPASS and SURMOUNT trials, FDA approved+ studies

Source

Synthetic dual GIP/GLP-1 receptor agonist

Overview

Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.

Mechanism of Action

Activates both GIP and GLP-1 receptors for synergistic metabolic effects, enhances insulin secretion while suppressing glucagon, reduces appetite via hypothalamic pathways, improves insulin sensitivity, promotes thermogenesis and energy expenditure.

Key Benefits

  • ✓Superior weight loss (20-25% body weight)
  • ✓Excellent glycemic control
  • ✓Reduced appetite and food intake
  • ✓Improved insulin sensitivity
  • ✓Better HbA1c reduction than GLP-1 alone
  • ✓Cardiovascular and metabolic benefits

Clinical Applications

Type 2 diabetesObesityMetabolic syndromeWeight managementInsulin resistance

Dosing Guidelines

Subcutaneous injection

Typical Dose2.5-15 mg (titrated weekly)
FrequencyOnce weekly
DurationLong-term maintenance

* Dosing should be individualized. Always consult with a qualified healthcare practitioner.

Research & Evidence

Evidence Level
Strong
Studies

SURPASS and SURMOUNT trials, FDA approved

Summary

SURMOUNT trials demonstrated 20-25% weight loss, superior to semaglutide. SURPASS trials showed excellent glycemic control. FDA approved for diabetes (Mounjaro) and obesity (Zepbound). Emerging as most effective pharmacological weight loss agent.

Safety Information

Potential Side Effects

  • •Nausea
  • •Diarrhea
  • •Vomiting
  • •Constipation
  • •Abdominal pain
  • •Injection site reactions
  • •Fatigue

Contraindications

  • Medullary thyroid carcinoma history
  • MEN 2 syndrome
  • Pregnancy
  • Breastfeeding
  • Severe GI disease

Interactions

  • ⚠Delays gastric emptying
  • ⚠May affect oral medication absorption
  • ⚠Potentiates insulin

Quick Facts

CategoryMetabolic
SourceSynthetic dual GIP/GLP-1 receptor agonist
Legal StatusFDA approved for type 2 diabetes and obesity
Gabriel Brain Score
94/ 100

Source Your Protocol

Our preferred peptide partner offers lab-tested, COA-verified peptides with optional physician oversight. Sourced from US-regulated facilities.

Related Peptides

Retatrutide

Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.

EmergingLearn more →

Semaglutide

Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.

StrongLearn more →

Survodutide

Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

EmergingLearn more →